NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 3,720 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,720 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $6.10, for a total value of $22,692.00. Following the completion of the sale, the insider now owns 5,499,065 shares of the company’s stock, valued at $33,544,296.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The stock was sold at an average price of $6.29, for a total value of $30,682.62.
• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Price Performance

Shares of NASDAQ NPCE traded down $0.20 during midday trading on Tuesday, reaching $6.00. 5,141 shares of the stock traded hands, compared to its average volume of 95,523. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The stock has a market capitalization of $172.61 million, a PE ratio of -5.04 and a beta of 1.78. NeuroPace, Inc. has a one year low of $5.73 and a one year high of $18.15. The company’s 50 day moving average is $7.04 and its 200 day moving average is $8.31.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same period in the prior year, the company earned ($0.36) EPS. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, equities research analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of NeuroPace

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Vanguard Group Inc. raised its holdings in NeuroPace by 18.3% during the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the period. Acadian Asset Management LLC raised its holdings in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after buying an additional 21,703 shares during the period. Bank of New York Mellon Corp purchased a new stake in NeuroPace during the 2nd quarter valued at $257,000. Finally, XTX Topco Ltd raised its holdings in NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on NPCE. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th. Wells Fargo & Company dropped their price target on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Finally, Morgan Stanley dropped their price target on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, NeuroPace presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.